BACKGROUND: As part of EUROCAT's surveillance of congenital anomalies in Europe, a statistical monitoring system has been developed to detect recent clusters or long-term (10 year) time trends. The purpose of this article is to describe the system for the identification and investigation of 10-year time trends, conceived as a ''screening'' tool ultimately leading to the identification of trends which may be due to changing teratogenic factors. METHODS: The EUROCAT database consists of all cases of congenital anomalies including livebirths, fetal deaths from 20 weeks gestational age, and terminations of pregnancy for fetal anomaly. Monitoring of 10-year trends is performed for each registry for each of 96 non-independent EUROCAT congenital anomaly subgroups, while Pan-Europe analysis combines data from all registries. The monitoring results are reviewed, prioritized according to a prioritization strategy, and communicated to registries for investigation. Twenty-one registries covering over 4 million births, from 1999 to 2008, were included in monitoring in 2010. CONCLUSIONS: Significant increasing trends were detected for abdominal wall anomalies, gastroschisis, hypospadias, Trisomy 18 and renal dysplasia in the Pan-Europe analysis while 68 increasing trends were identified in individual registries. A decreasing trend was detected in over one-third of anomaly subgroups in the Pan-Europe analysis, and 16.9% of individual registry tests. Registry preliminary investigations indicated that many trends are due to changes in data quality, ascertainment, screening, or diagnostic methods. Some trends are inevitably chance phenomena related to multiple testing, while others seem to represent real and continuing change needing further investigation and response by regional/national public health authorities. Birth Defects Research (Part A) 91:S31-S43,
INTRODUCTION
EUROCAT is a network of population-based registries for the epidemiologic surveillance of congenital anomalies in Europe established in 1979 in the wake of the thalidomide epidemic. The desire to prevent another thalidomide tragedy by detection of any new teratogenic drug or indeed any teratogenic environmental chemicals (EUROCAT, 2004 ) is related to the following EUROCAT objectives: to provide essential epidemiologic information on congenital anomalies in Europe; to facilitate the early warning of new teratogenic exposures; and to act as an information and resource center for the population, health professionals, and managers regarding clusters, exposures, or risk factors of concern. Statistical monitoring is one of the activities contributing to surveillance of teratogenic exposures. It is primarily performed to detect any previously unrecognized or unusual changes in frequency of congenital anomalies over both the short and long term which may indicate potential cause for concern where there is no specific prior hypothesis about exposure. It is also used in conjunction with other approaches where there are specific hypotheses-driven questions (e.g., whether neural tube defects [NTDs] are decreasing due to rising of periconceptional folic acid status). It is essentially a screening method to scrutinize data regularly and systematically, and hence is also useful as a data quality control system.
EUROCAT Central Registry performs annual statistical monitoring for clusters within the most recent 2-year period, short-term trends (5 years), and long-term trends (10 years), with a protocol and reporting process for preliminary investigation of clusters and trends (EUROCAT, 2010a , EUROCAT, 2010b . In this article, we describe the EUROCAT statistical monitoring system for the detection and investigation of long-term (10 year) trends in congenital anomalies illustrated with data from the most recent monitoring period, from 1999 to 2008.
METHODS Data
The EUROCAT database consists of all cases of congenital anomalies notified by member registries including liveborn cases, cases resulting in fetal deaths from 20 weeks gestation, and cases that were terminated after prenatal diagnosis of a congenital anomaly (EUROCAT Report 9, Paper 1). One case can have up to nine malformation or syndrome codes, coded to World Health Organization International Classification of Diseases (ICD)-British Pediatric Association (ICD10, Q chapter; ICD9, 740-759). The EUROCAT Data Management Program (EDMP) automatically assigns all cases of congenital anomaly to one or more of the 96 EUROCAT congenital anomaly subgroups (EUROCAT, 2005) . Each major organ subgroup (shown in gray in Table 1 ) is made up of a hierarchical structure of subgroups (e.g., spina bifida within NTDs within the nervous system). One case can be assigned to more than one subgroup, but each case is only counted once within any subgroup. Cases with chromosomal anomalies are only included in the monitoring of chromosomal subgroups as chromosomal anomalies are etiologically different from non-chromosomal anomalies.
Statistical monitoring for 10-year trends is conducted centrally for full member registries that transmit anonymized individual data by the annual transmission deadline of February 15 of each year (leaving a full year elapsed from the year of birth to cover late diagnoses and registration processes). In 2010, 21 eligible registries covering a total of 600,000 births per annum transmitted data to 2008 (19 registries) or 2007 (2 registries). Registries varied in size from a coverage of 4000 to 74,000 births per year.
Statistical Methods for the Detection of Trends
Tests for trend are performed for each congenital anomaly subgroup for each registry based on the number of cases per year of birth and number of births per year. The major organ subgroups are included in the monitoring mainly for tracking of data quality rather than for their interest in relation to teratogens, since they tend to be very heterogeneous. A ''Pan-Europe'' analysis additionally adds all registries together into one single European average figure (without weighting). Years are grouped into 2-year intervals. A trend test is not performed on a congenital anomaly subgroup if the expected number of cases per 2-year interval is <5 and if the observed number of cases in any 2-year interval is <2.
Change over time is tested using the Cochran-Armitage test that tests for trends in binomial proportions as described by Agresti (2002) . The test is divided into the trend component (''test for trend'') and a component for departure from linear trend (''test for non-linear change''). The test for trend identifies evidence of an increasing or decreasing trend in prevalence. The test for non-linear change identifies change over time that is not linear.
As these analyses by the Central Registry are designed to flag potentially changing patterns of prevalence in specific anomalies, which are unusual enough for further investigation by local registries, no adjustment is made for multiple hypothesis testing.
For simplicity of reporting, results are classified as follows:
No significant change in prevalence over time: p ! 0.05 for both linear and non-linear components.
Significant increasing or decreasing trend: p < 0.05 for trend and p ! 0.01 for non-linear change.
Significant non-linear change: p < 0.05 for non-linear change and p > 0.05 for trend; or p < 0.01 for non-linear change and p < 0.05 for trend.
For Down syndrome, an additional analysis corrects for maternal age and in utero survival (EUROCAT, 2010a) .
Each registry receives an Excel file (Microsoft, Redmond, WA) of the output showing the number of cases and test for trend results per subgroup (EUROCAT, 2010a) , as well as a file with graphical representation of the congenital anomaly subgroups with statistically ''significant'' change over time showing the rate of change for significant linear trends. Centrally, all results are presented in a single summary spreadsheet to facilitate the identification of patterns across registries or across subgroups.
All statistical tests and output are programmed in the EDMP and thus available to member registries so that they can conduct monitoring earlier, or conduct monitor-S32 LOANE ET AL. 
Central Coordination and Timetable
Central Registry runs the monitoring in March each year (Fig. 1) . The results are reviewed by the Steering Committee as per the prioritization strategy (below) to identify possible areas of concern and to direct central and local registry investigations. The results are then sent to registries for investigation, with preliminary investigations completed by the Registry Leaders Meeting in early June. Investigation Reports are sent back to the Central Registry to compile into the Annual Statistical Monitoring Report (EUROCAT, 2010b) . All investigation reports, including investigations of clusters or trends that were detected locally using more up-to-date data (Fig. 1) , are included in the annual Statistical Monitoring Report, which is sent to European Union (EU) DGSanco and made openly available on the EUROCAT website. The responsibility for disseminating the report (or local extracts) to regional or national health authorities lies with the local registries.
Prioritization Strategy
Inevitably, repeated annual monitoring will increase many chance findings. Rather than adjust these statistically Prob, probability; NLC, non-linear change; NTDs, neural tube defects; DT, decreasing trend; NS, not significant; CHD, congenital heart defect; IT, increasing trend.
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for multiple testing, a prioritization strategy is used to prioritize trends considered most worthy of investigation:
Examine Pan-Europe results with significant findings.
Prioritize increasing trends over decreasing trends, and prioritize decreasing trends over non-linear change.
Prioritize strong trends over weak trends, in terms of slope/percentage change, and prioritize low p values.
Prioritize trends with evidence of consistency across individual registries.
Differentiate between new and continuing trends (compared to previous year's monitoring).
Prioritize trends where there is prior concern about change in frequency of the anomaly or a potentially related exposure.
Prioritize well-defined subgroups over major organ system or heterogeneous subgroups.
Examine all individual registry significant results.
Identify registries with many subgroup trends that may reflect changes in overall ascertainment.
Prioritize increasing trends as above. Prioritize investigation of individual registry trends that correspond to significant Pan-Europe findings.
Prioritize continuing trends (since previous year's statistical monitoring) which seem robust to repeated analysis.
Prioritize strong trends over weak trends, in terms of slope/percentage change, and prioritize lower p values.
Prioritize trends which take the registry prevalence away from the EUROCAT average rather than trends which seem to ''normalize'' the registry.
Guidelines for Local Registry Preliminary Investigations
EUROCAT provides registries with guidelines on how to conduct preliminary investigations of identified long-term trends, as well as short-term trends and clusters (guidelines available in the online Appendix; and in Protocol, EUROCAT, 2010a). Investigations include case verification; and verification of changes in diagnostic or notification methods in the region. A template was designed to simplify reporting and classification of the results of preliminary investigations, (EUROCAT, 2010a) .
The level of investigation is subject to available local resources and varies between registries. Some registries do extensive checking and cross-referencing registry data with hospital records, while others are unable to do this due to patient confidentiality issues or insufficient resources. 
RESULTS

Detection of Trends
Pan-Europe trend tests were performed for 95 of the 96 subgroups of congenital anomalies included in central monitoring for 21 registries combined covering 4.2 million births, from 1999 to 2008, with the adjusted Down syndrome results added (Table 1) . Sixty of the subgroups showed significant trend or non-linear change over time.
Significant increasing Pan-Europe trends over time were identified in five anomaly subgroups (Fig. 2) of which three were independent (hypospadias, renal dysplasia, and Edward syndrome/Trisomy 18) and two were hierarchical subgroups reflecting the same trend (anomalies of abdominal wall and its component subgroup gastroschisis). All of these trends were identified in the previous statistical monitoring report up to 2007 up to (EUROCAT, 2010b , and all showed significant individual registry results for between 2 and 5 of the 21 registries ( Table 2 ). The rate of increase per 2-year interval ranged from 2 to 6% (Table 1) .
Decreasing Pan-Europe trends were detected in 36 anomaly subgroups with a decrease in rate per 2-year interval of 2 to 17%, of which 22 were new decreasing trends and 14 were ''continuing'' decreasing trends that were identified in the previous statistical monitoring report to (EUROCAT, 2010b . These included some non-independent decreasing trends (e.g., trends in NTD and two of its component subgroups, and trends in severe congenital heart defects [CHD] and six of its component subgroups). Twelve of the decreasing trends were identified in four or more individual registries, (Table 2) . Pan-Europe analysis detected some decreasing trends in subgroups where numbers in individual registries were too small for analysis, such as anophthalmos and single ventricle ( Table 2 ). The largest percentage change tended to be associated with heterogeneous organ system subgroups. Nineteen anomaly subgroups showed significant Pan-Europe non-linear change (Table 1) .
A total of 1190 chi-square tests were performed (Table  2) for the 21 individual registries across 96 subgroups (plus adjusted Down syndrome analysis), of which 38% returned ''significant'' results: 68 increasing trends, 201 decreasing trends, and 189 non-linear change. Tests were not performed in 847 registry/anomaly combinations (738 due to small numbers, 105 due to registry change from ICD9-10 coding within the monitoring period, and 4 for adjusted Down syndrome analyses as registries had no maternal age information for births in their region).
Eight anomaly subgroups were not tested in any registry due to small numbers ( Table 2) .
The subgroup ''All non-chromosomal anomalies'' showed some sort of significant change in all individual registries, whether increasing (2 registries), decreasing (8 registries), or non-linear change (11 registries).
The maximum number of subgroups showing increasing trends per registry was nine ( Table 2 ). The maximum number of subgroups showing decreasing trends per registry was 29 (Table 2) .
Preliminary Investigations into Increasing and
Decreasing 10-year Trends
Registries were asked to investigate all individual registry increasing trends (n 5 68), but discussion at the Registry Leaders Meeting was particularly focused on those that were significant at the Pan-Europe level, and those that showed an increase in multiple registries.
Registry preliminary investigation reports were available for 62 of the 68 increasing trends (91%). Diagnostic or data quality issues such as changes in case ascertainment, definition and inclusion criteria, or diagnostic methods accounted for 63% (n 5 39) of the increasing trends. Registries reported that 11% of the increasing trends were due to known demographic changes in maternal age: gastroschisis (one registry), chromosomal anomalies (one registry), Down syndrome/trisomy 21 (two registries, as shown by the non-significant adjusted Down syndrome trend), Edward syndrome/trisomy 18 (two registries), and Klinefelter's syndrome (one registry). Local registry investigations are ongoing into five increasing trends (8%) felt to be of concern in relation to potential changes in teratogenic exposures: abdominal wall defects, gastroschisis (which accounts for the abdominal wall defects trend), genital anomalies, hypospadias, and cleft lip with or without palate. Six percent of trends were not confirmed locally as trends either did not continue with the addition of more recent data or the anomaly subgroup was considered too heterogeneous (mainly major organ subgroups) for the trend to be of interest. Registries reported that 11% (n 5 7) of increasing trends could await further local surveillance. Four of the seven were new trends, three of which were increasing only in the registry.
Following Steering Committee review of the monitoring results, five anomalies with decreasing trends reported in four or more registries, as well as PanEurope, were prioritized for investigation by the 13 registries involved (Fig. 3) . Three of these were continuing trends reported in the previous statistical monitoring report (EUROCAT, 2010b ; NTD, spina bifida, and hip dislocation), for which investigations had not yet been requested (the previous year registries had reported only on increasing trends). Anorectal atresia showed a new decreasing trend. Severe CHD as a new subgroup combining 13 other cardiac subgroups was included in monitoring for the first time in 2010.
Registry preliminary investigation reports were available from 11 of the 13 registries with one or more of the selected decreasing trends. For NTD and its component spina bifida, of six registries investigating trends, four found no explanation and concluded the trend might be real (given prior interest in folic acid), and two identified Table 2 Long-term Trends by Registry and by Congenital Anomaly Subgroup, 21 EUROCAT Registries, 1999 to 2008 S40 LOANE ET AL. Table 2 Long-term Trends by Registry and by Congenital Anomaly Subgroup, 21 EUROCAT Registries, 1999 to 2008 * Too few cases to run analysis. § Incomplete or missing specification of ICD 9 codes. /, significant increasing trend; \, significant decreasing trend; $, non-linear change over time, NTD, neural tube defects; CHD, congenital heart defects; malf, malformation.
X 5 Data excluded from analysis. Registries must have used ICD10 coding for the whole period 1999 to 2008 to be included in surveillance of these subgroups.
M 5 Maternal age denominators unavailable or incomplete (>20% unknown) for monitoring period.
Highlighted cells: significant in Pan-Europe trend.
problems with the completeness or confirmation of data. For severe CHD, two of four registries investigating found no explanation, one was following up a coding problem found, and another could not further confirm cases due to data protection issues. For hip dislocation, of four investigating registries, three reported known changing screening and diagnostic systems in their regions as a likely explanation, and one judged that there had been a reporting change but noted that their rate had been much higher than the EUROCAT average. For anorectal atresia, of three registries reporting, two found no explanation, and one noted again that their prevalence had been much higher than the EUROCAT average.
DISCUSSION
We have reported a statistical monitoring system for identifying potential trends in congenital anomaly prevalence in the EUROCAT network. This system has been evolving over the last 5 years, and will continue to be refined. It is likely that country will be introduced as an intermediate level of analysis where there is more than one registry per country, maternal age adjustment will be added to the total chromosomal and Trisomy 13 and 18 subgroups, as is now done for Down syndrome, and that the prioritization strategy will be more clearly reflected in the presentation of results, including discounting the major organ subgroups. We are working on further refining the prioritization strategy and process, and improving the consistency and coordination of investigations across registries and centrally. Nevertheless, this is only a screening system for areas of concern -where there is concern, more sophisticated statistical analysis and investigation of exposure hypotheses is done to take demographic heterogeneity across Europe into account.
For four anomalies (contributing to five anomaly subgroups), there is consistent evidence of increasing trends. The trend in gastroschisis is of continuing concern (Loane et al., 2007) , and although reported worldwide in the past, it now seems to be particularly a U.K. phenomenon. Trisomy 18 is under separate investigation in relation to whether it can be explained by changes in maternal age, and by earlier detection of cases detected antenatally, which would otherwise not have survived to late pregnancy and diagnosis. The increase in hypospadias will be investigated, particularly in relation to a change in definition in 2005 when glanular hypospadias was no longer excluded as a minor anomaly. A study of renal dysplasia is also in progress.
Decreasing trends, however, are much more common than increasing trends, and overall this can possibly be considered a ''good news'' story. In particular, evidence that NTD (and its components subgroups spina bifida and anencephaly) has recently started decreasing may indicate an improvement in periconceptional folate status (EUROCAT, 2009a) . A decrease in severe CHD (and six of its component CHD subgroups) has also been noted in Canada (Prsa et al., 2009) and is under further investigation (Dolk et al., 2010, Dolk et al., in press, Khoshnood, submitted for publication). Other trends across Europe, including anorectal atresia, will be investigated. Some of the rarer subgroups can only be feasibly investigated centrally, and heterogeneity within some subgroups (such as disorders of the skin) and coding issues in others are being addressed. Meta-analysis techniques to investigate the relationships between different anomaly subgroups are possible, but we believe that more hypothesis-driven investigations of relationships will probably prove more fruitful, and we limit ourselves to observing the co-occurrence of trends in different subgroups, such as NTD and severe CHD (Dolk et al., 2010) .
Many trends in individual registries are found to result from changes in case ascertainment by the registry due to changes in sources of information, or changes in diagnostic methods or screening. The EUROCAT monitoring system serves as a data quality monitoring system as well as teratogen surveillance. Although investigation of trends can be a time consuming task for registries, it is an essential part of surveillance, whether or not a ''true'' underlying trend is found. Changing data quality causes ''false-negative'' results in the monitoring system where real trends are not detected.
The test for trend used in this analysis operates under the null hypothesis of no linear trend in the proportions. The performance of the test for trend was compared to binomial and Poisson regression as alternative approaches. Using a subset of 434 registry/anomaly combinations, the results of the test for trend and binomial regression were in agreement in 82% of tests. Divergence of results could not always be easily explained, although differences frequently occurred when the observed number of cases was below the minimum required for the test for trend.
In the absence of an adjustment for multiple hypothesis testing, it is clear that many spurious results will be obtained. However, the test for trend is intended as a screening tool and a high sensitivity is preferred at the expense of a low specificity, followed up by a prioritization strategy to focus on the anomalies of most interest within the resources available for investigation. A lower p value cutoff could have been chosen, but this would have very little affect on the Pan-Europe results and of all significant individual registry results, 72% were significant at p < 0.01. A lower p value cutoff would tend to select even more of the larger subgroups or larger registries.
The Pan-Europe analysis is a crude unweighted adding of registries. It is difficult to implement any more sophisticated statistical techniques as a routine screening tool, for example, multilevel analysis with registries as random effects because of the small numbers often encountered in individual congenital anomaly subgroups or 
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small registries. We are finding the crude tool adequate for screening, with more sophisticated subsequent analysis adapted to the frequency and characteristics of the anomaly of concern. Currently, monitoring for 10-year trends covers 600,000 births per year in Pan-Europe analysis, or 11% of EU births. This is not necessarily a representative sample of the EU, and care needs to be taken in extrapolation to the entire EU. A central concern for surveillance is timeliness, although this is less important for the detection of 10-year trends than the detection of recent clusters. The Central Registry receives data annually, allowing a year's interval for diagnosis and ascertainment of cases, and performs monitoring very shortly after data receipt. Individual registries can tailor earlier monitoring to their own data collection processes, and the statistical analyses are programmed within the common software (EDMP) with a user friendly interface to facilitate this. The provision of software to member registries is part of the ''added value'' of funded central coordination. However, few registries have so far implemented earlier monitoring EUROCAT, 2010b and indeed some are not able to meet the central transmission deadline, although the number meeting the deadline has greatly improved over recent years.
EUROCAT statistical monitoring allows an overview of the situation in Europe, while providing ''added value'' to individual registries by setting their individual results in a wider context. EUROCAT statistical monitoring has evolved over time with annual discussion, review, and refinement of the monitoring methodology and process. A clearer designation of public health responsibilities and pathways by which issues of potential public health concern are acted upon are now needed.
